Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

Artículo original

Año: 2023

Galan-Gutierrez, M; Font-Ugalde, P; Padial, E; Hernandez-Montoya, C; Godoy, D; Armario-Hita, JC; Ruiz-Villaverde, R

Título: INTERNATIONAL JOURNAL OF DERMATOLOGY

• Q1